Your Solutions
BIOMEDTRACKER
Real-time Event Tracking & Drug Development Analysis
管線研發追蹤、獲批前景分析、商業資訊、調研報告
DATAMONITOR HEALTHCARE
Disease Competitive Analysis, 10-20 Years Market Forecast, KOL Insights
疾病競爭分析、10-20年市場預測、KOL專訪
Meet the team
Julie Guan (China)
Head of Strategic Accounts
Citeline
Youmin Zhu (China)
Client Success Manager
Citeline
Training & Help
We provide product training support via online sessions/pre-recorded materials, please click below to access relevant contents, or reach out to this email for any customized training request: [email protected]
我們提供各產品的使用培訓支持，請點擊下列查閲相關培訓資源，若有特定培訓需求或安排則可聯絡：[email protected]
For access or technical issues, please contact your dedicated support team via 'Meet the Team', or contact Client Service team via below email:
若有任何登錄問題，請切換至Meet the Team版面並聯絡對接服務團隊，或可聯絡全球/亞太客服團隊：
Global - [email protected] (English only)
APAC - [email protected] (via English/Chinese)
Require Research Support?
Ask-the-Analyst™
Ask-the-Analyst™
Your status as a loyalty partner includes unlimited access to our highly acclaimed Ask-the-Analyst™ service. With a 24-hour response time, Ask-the-Analyst offers you authoritative information to help you make faster, smarter business decisions.
作爲重點合作夥伴，貴司用戶均可無限量使用「Ask-the-Analyst™」分析師咨詢服務。分析師團隊將會在24小時内回復（工作日），并爲您提供信息收集或專業見解，最終助您做出更快、更明智的業務決策。
Our Ask-the-Analyst team of industry experts leverages the complete suite of pharma intelligence products and publicly available sources to bring you the answers you’re looking for, while your information and all questions received are strictly confidential.
由業界專家組成的Ask the Analyst團隊將結合内部數據與公開領域資源爲您提供相關信息支持，您的個人資訊與提問内容均會被嚴格保密。
Latest Pharma Monthly Newsletter
Edition: July 2026
EDITORIAL CONTENTS (incl. Podcasts, Webinars)
- Webinar: From Protocol Design to Patient Recruitment: Closing the Gap with Real-World Data (AUG 27, 9am SGT | Register)
- Webinar: Beyond Cough & Cold: OTC In the Age Of Prevention (SEP 03, 10am EST | Register)
- Webinar: Where Precision Drives Progress: Meeting the Rising Complexity of Modern Clinical Trials (Watch Now)
DEALS & FINANCING (incl. M&As, Licensing, Financing)
- M&A: Vertex to Acquire Crinetics Pharmaceuticals for $10B
- M&A: Lilly to Acquire AtaiBeckley for up to $3.8B
- M&A: Tempus AI to Acquire Personalis in $1.5B Deal
- Licensing: AstraZeneca Licenses Global Rights to Dizal's Zegfrovy for up to $1.50B ($600M upfront)
- Licensing: Johnson & Johnson and Sail Biomedicines Collaborate to Develop New Class of In Vivo CAR-T Therapies totalling $925M ($785M upfront)
- Financing: Apnimed Nets $220.8M Via IPO; Overallotment Fully Exercised
- Financing: Chai Discovery Secures $400M in a Series C Financing to Advance AI-Driven Molecular Design
- Financing: AdvanCell Raises $315M in Upsized Series D Round
KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)
- Positive: AstraZeneca | Sonesitatug vedotin claims first CLDN18.2 ADC Phase III win in gastric cancer
- Positive: GSK | Ris-Rez demonstrates overall survival benefit in relapsed SCLC, marking the first Phase III win for a B7-H3-targeted ADC in any tumor type
- Positive: HUYA | Hiyasta gains vital Phase III win, as competition in the frontline melanoma treatment landscape intensifies
- Positive: Pfizer | LITFULO (ritlecitinib) Delivers Landmark Dual-Endpoint Win in the Largest Oral Nonsegmental Vitiligo (NSV) Trial Ever Conducted
- Positive: Kailera | Hengrui's GLP-1/GIP dual agonist ribupatide shows HbA1c reductions up to 2.67% in treatment-naive Chinese type 2 diabetes patients
- Negative: Novo Nordisk | ZEUS sends a bolt of pain through Novo Nordisk’s cardiovascular strategy
- Negative: Ionis | Disappointing Phase 3 results for Ionis and AZ’s Wainua (eplontersen) in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)
RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)
- Report: Oncology's Next Decade: The Therapies and Players Reshaping a $400bn Future (Link)
- Report: Gene, Cell, & RNA Therapy Landscape Q2 2026 (Link)
- Report: Article Pack: AI in Biopharma
- Report: IgA Nephropathy: Five Trends Reshaping the Market
- Report: Conference - Post-EHA 2026 | Post-ICPR 2026
- Report: Medtech Market Analysis - Cardiac Ablation Catheters | Liquid Biopsy Oncology | Point-of-Care Diagnostics
- Report: Epi & Market Forecast - Alopecia Areata | Hereditary Angioedema
- Report: KOL Interview - Alopecia Areata | Hemophilia | Hereditary Angioedema | IgAN | Multiple Sclerosis | NASH | Schizophrenia | Type 1 Diabetes
Latest Editorial Podcasts
